2009•Journal of Medical VirologyOpen access
A real‐time PCR assay to identify and discriminate among wild‐type and vaccine strains of varicella‐zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses
Ruth Harbecke, Michael N. Oxman, Beth Arnold, Charlotte C. Yu Ip, Gary R. Johnson, Myron J. Levin, Lawrence D. Gelb, Kenneth E. Schmader, Stephen E. Straus, Hui Wang, Peter F. Wright, Constance T. Pachucki, Anne A. Gershon, Robert D. Arbeit, Larry E. Davis, Michael S. Simberkoff, Adriana Weinberg, Heather Williams, Carol Cheney, Luba Petrukhin, Katalin G. Abraham, Alan Shaw, Susan B. Manoff, Joseph M. Antonello, Tina Green, Yue Wang, Charles Y. Tan, Paul M. Keller, for the Shingles Prevention Study Group
Open full text 73 citations
Abstract
A real-time PCR assay was developed to identify varicella-zoster virus (VZV) and herpes simplex virus (HSV) DNA in clinical specimens from subjects with suspected herpes zoster (HZ; shingles). Three sets of primers and probes were used in separate PCR reactions to detect and discriminate among wild-type VZV (VZV-WT), Oka vaccine strain VZV (VZV-Oka), and HSV DNA, and the reaction for each virus DNA was multiplexed with primers and probe specific for the human beta-globin gene to assess specimen adequacy. Discrimination of all VZV-WT strains, including Japanese isolates and the Oka parent strain, from VZV-Oka was based upon a single nucleotide polymorphism at position 106262 in ORF 62, resulting in preferential amplification by the homologous primer pair. The assay was highly sensitive and specific for the target virus DNA, and no cross-reactions were detected with any other infectious agent. With the PCR assay as the gold standard, the sensitivity of virus culture was 53% for VZV and 77% for HSV. There was 92% agreement between the clinical diagnosis of HZ by the Clinical Evaluation Committee and the PCR assay results.